Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib
Authors
Keywords
-
Journal
HEPATOLOGY RESEARCH
Volume 42, Issue 9, Pages 879-886
Publisher
Wiley
Online
2012-02-29
DOI
10.1111/j.1872-034x.2012.00991.x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy
- (2011) P Österlund et al. BRITISH JOURNAL OF CANCER
- Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib
- (2011) Manabu Morimoto et al. HEPATOLOGY RESEARCH
- Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib
- (2010) B. Vincenzi et al. ONCOLOGIST
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- (2010) Riccardo Lencioni et al. SEMINARS IN LIVER DISEASE
- Blood pressure as a potential biomarker of the efficacy angiogenesis inhibitor
- (2009) B. I. Levy ANNALS OF ONCOLOGY
- Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma
- (2009) P. Bono et al. ANNALS OF ONCOLOGY
- Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer
- (2009) A. Ravaud et al. ANNALS OF ONCOLOGY
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab
- (2008) M. Scartozzi et al. ANNALS OF ONCOLOGY
- Prospective Study of the Cutaneous Adverse Effects of Sorafenib, a Novel Multikinase Inhibitor
- (2008) Julien Autier et al. ARCHIVES OF DERMATOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Dermatologic symptoms associated with the multikinase inhibitor sorafenib
- (2008) Caroline Robert et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study
- (2008) Jean-Philippe Spano et al. LANCET
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search